Nolan Priedigkeit
@npriedig.bsky.social
physician scientist | breast cancer, genomics, gene and RNA therapy | dfci breast onc, broad institute
Reposted by Nolan Priedigkeit
Congratulations to BCRF investigator Dr. Steffi Oesterreich for receiving this year’s AACR (@theaacr.bsky.social) Distinguished Lectureship in Breast Cancer Research Award at #SABCS24. She has made groundbreaking contributions in translational breast cancer research. @sabcs.bsky.social
December 12, 2024 at 10:11 PM
Congratulations to BCRF investigator Dr. Steffi Oesterreich for receiving this year’s AACR (@theaacr.bsky.social) Distinguished Lectureship in Breast Cancer Research Award at #SABCS24. She has made groundbreaking contributions in translational breast cancer research. @sabcs.bsky.social
Reposted by Nolan Priedigkeit
Check out this bombshell publication by Michael Fischbach @mfgrp.bsky.social and coworkers @stanford-chemh.bsky.social @stanfordmedicine.bsky.social, imagine a cancer immune therapy/vaccine where treatment begins and ends with a painless topical skin treatment! 🤯
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Discovery and engineering of the antibody response to a prominent skin commensal - Nature
Nature - Discovery and engineering of the antibody response to a prominent skin commensal
www.nature.com
December 11, 2024 at 7:26 PM
Check out this bombshell publication by Michael Fischbach @mfgrp.bsky.social and coworkers @stanford-chemh.bsky.social @stanfordmedicine.bsky.social, imagine a cancer immune therapy/vaccine where treatment begins and ends with a painless topical skin treatment! 🤯
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Nolan Priedigkeit
More than 75 Nobel Prize winners signed a letter urging senators not to confirm Robert F. Kennedy Jr. to lead the Department of Health and Human Services. The letter marks the first time in recent memory that Nobel laureates have banded together against a cabinet choice. nyti.ms/41uQueD
December 10, 2024 at 2:17 AM
More than 75 Nobel Prize winners signed a letter urging senators not to confirm Robert F. Kennedy Jr. to lead the Department of Health and Human Services. The letter marks the first time in recent memory that Nobel laureates have banded together against a cabinet choice. nyti.ms/41uQueD
Reposted by Nolan Priedigkeit
Intravenous administration of blood–brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system
"A system that facilitates delivery into the CNS through γ-secretase-mediated transcytosis."
www.nature.com/articles/s41...
"A system that facilitates delivery into the CNS through γ-secretase-mediated transcytosis."
www.nature.com/articles/s41...
Intravenous administration of blood–brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system - Nature Biotechnology
Biomacromolecules are delivered across the blood–brain barrier when administered systemically.
www.nature.com
December 10, 2024 at 12:22 AM
Intravenous administration of blood–brain barrier-crossing conjugates facilitate biomacromolecule transport into central nervous system
"A system that facilitates delivery into the CNS through γ-secretase-mediated transcytosis."
www.nature.com/articles/s41...
"A system that facilitates delivery into the CNS through γ-secretase-mediated transcytosis."
www.nature.com/articles/s41...
Reposted by Nolan Priedigkeit
The @dfcibreastonc.bsky.social team is on its way— see you all soon in San Antonio! #SABCS24
December 9, 2024 at 2:49 PM
The @dfcibreastonc.bsky.social team is on its way— see you all soon in San Antonio! #SABCS24
Reposted by Nolan Priedigkeit
Estimated 6 Million deaths from breast, cervical, colorectal, lung, and prostate cancers were averted in the US from 1975 to 2020 due to Prevention, Screening, and Treatment Advances @jama.com
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Estimation of Cancer Deaths Averted From Prevention, Screening, and Treatment Efforts, 1975-2020
This model-based study using population-level cancer mortality data evaluates the association of prevention, screening, and treatment interventions with cumulative number of cancer deaths averted from...
jamanetwork.com
December 8, 2024 at 3:16 PM
Estimated 6 Million deaths from breast, cervical, colorectal, lung, and prostate cancers were averted in the US from 1975 to 2020 due to Prevention, Screening, and Treatment Advances @jama.com
jamanetwork.com/journals/jam...
jamanetwork.com/journals/jam...
Reposted by Nolan Priedigkeit
December 8, 2024 at 4:52 AM
Reposted by Nolan Priedigkeit
The next frontier of T cell therapeutics when the T also stands for tissue-targeting, such as brain or local immune response, via synthetic gene circuits
@science.org
science.org/doi/10.1126/...
science.org/doi/10.1126/...
science.org/doi/10.1126/...
@science.org
science.org/doi/10.1126/...
science.org/doi/10.1126/...
science.org/doi/10.1126/...
December 5, 2024 at 7:22 PM
The next frontier of T cell therapeutics when the T also stands for tissue-targeting, such as brain or local immune response, via synthetic gene circuits
@science.org
science.org/doi/10.1126/...
science.org/doi/10.1126/...
science.org/doi/10.1126/...
@science.org
science.org/doi/10.1126/...
science.org/doi/10.1126/...
science.org/doi/10.1126/...
Reposted by Nolan Priedigkeit
Zenocutuzumab, a HER2/3 bispecific, now approved for #NRG1 fusion positive NSCLC and pancreatic cancers. Best to use RNA-seq to find this fusion - DNA based NGS often misses it. Outcomes poor with standard therapy - this is an an important approval. #OncSky #LCSM
www.fda.gov/drugs/resour...
www.fda.gov/drugs/resour...
FDA grants accelerated approval to zenocutuzumab-zbco
On December 4, 2024, the FDA granted accelerated approval to zenocutuzumab-zbco for non-small cell lung cancer and pancreatic adenocarcinoma.
www.fda.gov
December 4, 2024 at 9:24 PM
Zenocutuzumab, a HER2/3 bispecific, now approved for #NRG1 fusion positive NSCLC and pancreatic cancers. Best to use RNA-seq to find this fusion - DNA based NGS often misses it. Outcomes poor with standard therapy - this is an an important approval. #OncSky #LCSM
www.fda.gov/drugs/resour...
www.fda.gov/drugs/resour...
Reposted by Nolan Priedigkeit
Big news. Dr. Druker literally tranformed care for chronic myelogenous leukemia.
His rationale for stepping down is a warning to centers everywhere - innovation takes vision and sustained commitment.
Lose the mission, lose the team.
His rationale for stepping down is a warning to centers everywhere - innovation takes vision and sustained commitment.
Lose the mission, lose the team.
December 4, 2024 at 10:26 AM
Big news. Dr. Druker literally tranformed care for chronic myelogenous leukemia.
His rationale for stepping down is a warning to centers everywhere - innovation takes vision and sustained commitment.
Lose the mission, lose the team.
His rationale for stepping down is a warning to centers everywhere - innovation takes vision and sustained commitment.
Lose the mission, lose the team.
Reposted by Nolan Priedigkeit
SONIA trial - Pts with ER+ breast cancer beginning treatment in the metastatic setting randomized to 1st line vs 2nd line use of CDK4/6 inhibitor (+ endocrine therapy). No sig difference in PFS.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Early versus deferred use of CDK4/6 inhibitors in advanced breast cancer - Nature
The phase 3 SONIA trial challenges the benefits of using cyclin-dependent kinase 4 and 6 inhibitors as a first-line compared with second-line treatment.
www.nature.com
November 29, 2024 at 6:16 PM
SONIA trial - Pts with ER+ breast cancer beginning treatment in the metastatic setting randomized to 1st line vs 2nd line use of CDK4/6 inhibitor (+ endocrine therapy). No sig difference in PFS.
www.nature.com/articles/s41...
www.nature.com/articles/s41...
Reposted by Nolan Priedigkeit
Pooled CRISPR screens with joint single-nucleus chromatin accessibility and transcriptome profiling go.nature.com/4hXER5O
Pooled CRISPR screens with joint single-nucleus chromatin accessibility and transcriptome profiling - Nature Biotechnology
MultiPerturb-seq profiles gene expression and chromatin accessibility in single-cell pooled CRISPR screen.
go.nature.com
November 21, 2024 at 2:26 PM
Pooled CRISPR screens with joint single-nucleus chromatin accessibility and transcriptome profiling go.nature.com/4hXER5O